

Potential for Environmental and Therapeutic Agents to Induce Immunotoxicity

**NTP Board of Scientific Counselors
Concept Review
October 26, 2004**



Purpose of the Contract

- ♦ **Develop and validate methods to evaluate modulation of immune function**
- ♦ **Evaluate immunomodulatory potential of agents of concern using a tiered testing panel**
- ♦ **Studies to define cellular and molecular events associated with modulation of immune function**

Historical Information

- ♦ Testing contract has been available since the 1980.
 - Proposals sought in 1985, 1990, 1995 and 2000
 - Current contractor is Virginia Commonwealth University
- ♦ Separate ITOX contracts for specific agents
- ♦ In house studies

Historical Information

- ♦ Current Contract
 - Five year contract with R &D and additional task options
- ♦ Proposed Contract
 - Three year base contract with five additional years, R & D and additional task options

Impact of NTP ITOX efforts

- ♦ **Developed tiered testing panel which has been the basis for regulatory guidelines and guidance in the field**
- ♦ **Provided leadership in evaluating predictive methods**
- ♦ **Risk assessment and extrapolation to human health**

Source of Nominations

- ♦ **NTP Chemicals of Interest**
- ♦ **Other Agencies**
- ♦ **ICCEC**
- ♦ **Academic Community**
- ♦ **General Public**

Current Annual Activities

- ♦ Immunomodulation
 - Generally in B6C3F1 mice and/or F344 rats
 - Exposure can be oral, i.p., dermal, dosed food or water
 - Inhalation exposures can be done as add on
 - 4 Range finding studies and 2 Protocol studies
- ♦ Hypersensitivity
 - Balb/c mice
 - 2 Compounds
- ♦ Autoimmunity
 - 1 Compound

Range Finding Studies to Screen for Immunomodulatory Effects

- ♦ Immunopathology
- ♦ Cell Mediated Immunity
- ♦ Humoral Mediated Immunity
- ♦ Non-Specific Immunity
- ♦ Cell Quantification

Chemicals Tested in Range Finding Studies

- ♦ Saquinavir
- ♦ Itraconazole
- ♦ AZT
- ♦ Nevirapine
- ♦ Echinacea purpurea
 - NTP Preparation
 - Commercial Prep
- ♦ Chloroform
- ♦ Chloramine
- ♦ Dibromoacetic Acid
- ♦ Dichloroacetic Acid
- ♦ Phenol
- ♦ 1,3-Dichloropropene

Chemicals Tested in Range Finding Studies (continued)

- ♦ Ethinyl Estradiol
- ♦ Vinclozolin
- ♦ Elmiron
- ♦ Patulin (Rat)
- ♦ Patulin (Mouse)
- ♦ Hexavalent Chromium (mouse)
- ♦ Hexavalent Chromium (rat x 2)

Full Protocol Studies to Evaluate Immunomodulatory Effects

- ♦ Immunopathology, Humoral Mediated Immunity and Cell Quantification from Range finding studies plus additional tests to assess:
- ♦ Cell Mediated Immunity
- ♦ Humoral Mediated Immunity
- ♦ Non-Specific Immunity
- ♦ Hematopoietic Stem Cells
- ♦ Host Resistance

Chemicals Tested in Protocol Studies

- ♦ Saquinavir
- ♦ Dibromoacetic Acid
- ♦ Chloroform
- ♦ Echinacea purpurea
- ♦ Elmiron

Assessment of the Potential to Induce Hypersensitivity

- ♦ **Local Lymph Node Assay**
 - ICCVAM protocol
 - Modification to evaluate systemic hypersensitivity
- ♦ **Mouse Ear Swelling Test**
- ♦ **Cell Quantification in LN**
- ♦ **Cytokine mRNAs**

Chemicals Tested for Potential to Induce Hypersensitivity

- ♦ **5- Amino-o-Cresol**
- ♦ **Pyrogallol**
- ♦ **Rifamycin**
- ♦ **Sodium Metasilicate**
- ♦ **Annatto**
- ♦ **Norbixin**

Potential to Influence Autoimmune Disease

♦ Models

- NZB Mouse (Systemic Lupus erythematosus)
- NOD mouse (Diabetes)
- Brown Norway Rat (Autoimmune skin and renal disease, SLE)

♦ Endpoints

- Quantification of autoantibodies, serum Ig levels, protein and glucose in urine, histology

Chemicals Evaluated for Potential to Induce or Exacerbate Autoimmune Responses

♦ Cadmium

- NZB Mouse
- Brown Norway Rat
- Mrl/lpr mouse

♦ Genistein

- NZB Mouse

♦ Echinacea

- NZB mouse

R & D Developmental Studies

- ♦ Tributyltin Oxide
- ♦ AZT
- ♦ Nevirapine
- ♦ Vinclozolin
- ♦ Ethinyl Estradiol
- ♦ CpG Oligonucleotide

R&D Studies

- ♦ Transgenic Mouse studies
- ♦ Immunotoxicogenomics studies
- ♦ *In vitro* methods
- ♦ Keyhole Limpet Hemocyanin as an alternative antigen
- ♦ ELISPOT technology
- ♦ Improving Delayed Type Hypersensitivity models
- ♦ Improving Host Resistance models
- ♦ Electronic Database

Products

- ♦ **Over 25 publications in peer-reviewed journals**
- ♦ **Mechanistic studies**
 - **Tissues from testing efforts used to conduct hypothesis driven research**
- ♦ **NTP Reports**

New Features for 2005

- ♦ **Routine evaluation of tissues using extended histopathology**
 - **Additional data needed for evaluation of sensitivity and specificity**

New Features for 2005

- ♦ **Routine collection of tissues for genomics studies**
 - **Correlation between altered function and changes in gene expression**
 - **Focused versus tissue-specific arrays**
 - **Can gene fingerprinting be used to screen for compounds that target the Immune system?**

New Features for 2005

- ♦ **Inclusion of developmental studies as a defined task**
 - **Evaluation of test methods**
 - **Identification of new endpoints to assess the developing immune system**
 - **Persistence of effects in adult animals**

Annual Activities

- ♦ Immunomodulation
 - 4 Range finding studies
 - 2 Protocol studies
 - 2 Developmental Studies
- ♦ Hypersensitivity
 - 2 Compounds
- ♦ Autoimmunity
 - 1 Compound

Options

- ♦ Test Additional Compounds
 - May be exercised in any year of the contract
 - Can increase capabilities by 35% of the total yearly level of effort
- ♦ Mechanistic Studies and Development of New Technology
 - May be exercised in any year of the contract
 - NTE 10% of base contract

Summary

- ♦ **Statement of work similar to previous contracts**
 - Routine inclusion of additional endpoints
 - Capacity can be increased through use of Task V options
- ♦ **Addition of task for evaluation of developmental immunotoxicity**
- ♦ **Shorter base contract with additional years as options**

Looking forward

- ♦ **Develop and validate methods to evaluate modulation of immune function**
 - Use of in vitro and genomics studies for screening
- ♦ **Evaluate immunomodulatory potential of agents of concern**
 - Focus on susceptible populations (neonates, aged animals) and specific diseases (autoimmunity)
- ♦ **Studies to define cellular and molecular events associated with modulation of immune function**
 - Not just yes and no, but why and how